Endoscopy 2021; 53(07): 739-743
DOI: 10.1055/a-1250-7786
Innovations and brief communications

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic microcystic serous cystic neoplasms: a retrospective study

Dongwook Oh*
1  Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
,
Sung Woo Ko*
2  Department of Gastroenterology, The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, South Korea
,
Dong-Wan Seo
1  Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
,
Seung-Mo Hong
3  Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
,
Jin Hee Kim
4  Department of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
,
Tae Jun Song
1  Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
,
Do Hyun Park
1  Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
,
Sung Koo Lee
1  Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
,
Myung-Hwan Kim
1  Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
› Institutsangaben
This study was supported by a grant from the Korean Health Technology R & D project, Ministry of Health & Welfare, Republic of Korea (HI16C1163).

Abstract

Background Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been increasingly used for the management of various solid pancreatic tumors. This study aimed to evaluate the feasibility and safety of EUS-RFA for serous cystic neoplasms (SCNs).

Methods 13 patients with microcystic SCNs with honeycomb appearance underwent EUS-RFA using a 19-gauge RFA needle. Before ablation, cystic fluid was aspirated until a thin layer of fluid remained.

Results EUS-RFA was successful in all patients. Seven patients underwent a single session and the remaining six patients underwent a second session of EUS-RFA. One patient (7.7 %) experienced self-limited abdominal pain after EUS-RFA. During a median follow-up period of 9.21 months (interquartile range [IQR] 5.93 – 15.38), the median volume of the SCNs decreased from 37.82 mL (IQR 15.03 – 59.53) at baseline to 10.95 mL (IQR 4.79 – 32.39) at the end of follow-up. A radiologic partial response was achieved in eight patients (61.5 %).

Conclusions EUS-RFA is technically feasible and showed an acceptable rate of adverse events for patients with SCNs. A long-term follow-up study is required to evaluate the efficacy of EUS-RFA.

* Equal first authors


Supplementary material



Publikationsverlauf

Eingereicht: 08. April 2020

Angenommen: 05. August 2020

Publikationsdatum:
15. Oktober 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany